Progress and introduction
of main products
Inhibition of human thymic stromal lymphopoietin (TSLP) has been proved to be an effective way to treat non-eosinophilic and eosinophilic asthma in recent clinical studies. LQ043H, independently developed by Novamab, is an inhaled Nanobody drug targeting TSLP, which is used to treat broad-spectrum moderate and severe asthma. LQ043H has good functional activity. LQ043H is directly delivered to the lungs,and take effect rapidly. Local administration of LQ043H could greatly reduce the risk of systemic toxicity and side effects. LQ043H is produced by Pichia pastoris fermentation, and its expression yield is up to 20g/L, which has the advantage of commercial promotion. In addition, this product has good stability and could be stored at normal temperature for 2 years, which is convenient for transportation and carrying. Therefore, LQ043H has great potential to become the world's first approved oral TSLP Nanobody that could treat broad-spectrum asthma, benefiting a wider range of asthma patients.
High pulmonary drug concentrations
Minimal systemic adverse effects
Produced by Pichia pastoris at high yield, lower cost
Thymic stromal lymphopoietin (TSLP) is a short-chain tetramine α Helical beam type I interleukin-2 (IL-2) family cytokines can induce monocytes to release T cells to attract chemokines, promote the maturation of dendritic cells, and drive the release of downstream T2 cytokines (including IL-4, IL-5, and IL-13), thus enhancing the production of IgE, mast cells and mucus, and increasing airway hyperresponsiveness. TSLP can also activate many types of cells involved in non-t2-driven inflammation. TSLP is a key mediator in various phenotypes of asthma. Antibodies targeting TSLP and its signal transduction are considered to be effective strategies for the treatment of asthma. LQ043H nanoantibody can effectively inhibit the combination of TSLP and TSLPR, block the signal pathway mediated by TSLP and TSLPR/IL7Ra, realize the eosinophilic (allergic and non-allergic) inflammation, non-eosinophilic inflammation and structural changes of the airway, and achieve the effect of relieving asthma.
Moderate and severe asthma、COPD
This product has been submitted to China IND application and will officially start the clinical phase I trial on February 22, 2023.